Reviva Pharmaceuticals shares rise 10.21% intraday after analysts give "Moderate Buy" rating.

Reviva Pharmaceuticals Holdings, Inc. surged 10.21% intraday after Roth Capital reiterated a "Buy" rating, as highlighted by MarketBeat. The firm’s recent analyst coverage, including a "Moderate Buy" average recommendation, likely boosted investor confidence. Notable events included participation in investor conferences and positive clinical data presentations for Brilaroxazine in schizophrenia trials, though these were older and less directly tied to the intraday move. The immediate catalyst appears to be the renewed analyst endorsement, which aligns with the stock’s sharp intraday rally.